Answers are grounded in this paper and cite their sources.
Background Cardiovascular disease is a major cause of morbidity and mortality in patients with chronic kidney disease and end-stage renal disease (ESRD). Dyslipidemia is a key focus of cardiovascular therapy and is characterized by hypertriglyceridemia mainly caused by lipoprotein lipase-mediated metabolism of ApoC-III in patients with ESRD. Pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, can be used regardless of renal function and inhibit ApoC-III expression in the liver. Case presentation We reported the cases of four patients on hemodialysis who met at least 175 mg/dL of triglycerides on the consecutive three tests between September 2022 and November 2022 and took 0.1 mg pemafibrate twice a day from November 2022 to May 2023. They experienced no adverse events after pemafibrate treatment. Pemafibrate significantly reduced triglyceride (TG) (302 ± 72 to 140 ± 50 mg/dL, p = 0.048), total cholesterol (187 ± 34 to 156 ± 48 mg/dL, p = 0.025), and Apo C-III (15.9 ± 8.2 to 12.6 ± 7.1, p = 0.030) levels. Apo A-II levels significantly increased after treatment (27.0 ± 6.1 to 37.1 ± 5.8, p = 0.041). Conclusions Pemafibrate decreased TG, total cholesterol, and Apo-CIII and increased Apo A-II without adverse events. Further study is needed to examine the favorable effects of pemafibrate on the risk of CVD.
No takes yet. Share an insight, caveat, or question.
Onishi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: